References
- McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four-dose treatment program. J Clin Oncol 1998; 8: 2825–2833
- Piro L D, White C A, Grillo-Lopex A J, et al. Extended Rituximab (anti CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 6: 655–661
- Czuczman M S, Grillo-Lopez A J, White C A, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17(1)268–17
- Hainswoth J D, Burns H A, Lisa H. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 2000; 95(10)3052–95
- Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-D2B8). Blood 1999; 7: 2217–2224
- Foran J M, Rohatiner A ZS, Cunningham D, et al. European phase 2 study of rituximab (chimeric anti CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 2: 317–331
- Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti CD20 antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase 2 study. Blood 2000; 92(6)1927–92
- Coiffier B, Lepage E, Herbrecht R, et al. Mabthera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomised GELA trial. ASH 2000 2000, Abstract #948
- Byrd J C, White C A, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 12: 1525–1527
- Weide R, Heymanns J, Koppler H. Induction of complete haematological remission after monotherapy with anti CD20 monoclonal antibody (rituximab) in a patient with alkylating agent resistant Waldenstrom's macroglobulinemia. Leukemia & Lymphoma 1999; 36((1–2))203–206
- Rambaldi A, Lazzari M, Manzoni C, et al. Molecular eradication of the BCL2/IgH gene after sequential therapy with CHOP and anti-CD20 (rituximab) monoclonal antibody in previously untreated follicular NHL patients. ASH 2000 2000, Abstract #3166
- Lee E J, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998; 92(9)3490–92
- Gjertsen B T, Hammerstrom J, Langholm R, et al. Rituxan (rituximab) therapy for chronic cold agglutinin disease. ASH 2000 2000, Abstract #3156
- Perotta A, Sunneberg A, Scott J, et al. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). ASH 1999 1999, Abstract #49
- Saleh M N, Gutheil J, Moor M, et al. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP). ASH2000 2000, Abstract #1086